JP2024505226A5 - - Google Patents
Info
- Publication number
- JP2024505226A5 JP2024505226A5 JP2023546047A JP2023546047A JP2024505226A5 JP 2024505226 A5 JP2024505226 A5 JP 2024505226A5 JP 2023546047 A JP2023546047 A JP 2023546047A JP 2023546047 A JP2023546047 A JP 2023546047A JP 2024505226 A5 JP2024505226 A5 JP 2024505226A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- modified
- modified oligonucleotides
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163143686P | 2021-01-29 | 2021-01-29 | |
| US63/143,686 | 2021-01-29 | ||
| PCT/US2022/014231 WO2022165122A1 (en) | 2021-01-29 | 2022-01-28 | Compounds and methods for modulating huntingtin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505226A JP2024505226A (ja) | 2024-02-05 |
| JP2024505226A5 true JP2024505226A5 (enExample) | 2025-02-05 |
Family
ID=82653847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546047A Pending JP2024505226A (ja) | 2021-01-29 | 2022-01-28 | ハンチンチンを調節するための化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240376469A1 (enExample) |
| EP (1) | EP4284504A4 (enExample) |
| JP (1) | JP2024505226A (enExample) |
| KR (1) | KR20230137958A (enExample) |
| CN (1) | CN116940683A (enExample) |
| AU (1) | AU2022213384A1 (enExample) |
| CA (1) | CA3210076A1 (enExample) |
| IL (1) | IL304218A (enExample) |
| MX (1) | MX2023008922A (enExample) |
| WO (1) | WO2022165122A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4423272A2 (en) * | 2021-10-29 | 2024-09-04 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| AU2024323589A1 (en) * | 2023-08-16 | 2026-03-05 | Les Laboratoires Servier | Oligonucleotides for modulating kcnt1 expression |
| EP4527927A1 (en) * | 2023-09-22 | 2025-03-26 | Medizinische Hochschule Hannover | Oligonucleotide-based strategies to combat respiratory viruses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105995A2 (en) * | 2004-04-14 | 2005-11-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP3626823A1 (en) * | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| ES2733708T3 (es) * | 2010-02-08 | 2019-12-02 | Ionis Pharmaceuticals Inc | Reducción selectiva de variantes alélicas |
| JP6018506B2 (ja) * | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 対立遺伝子多様体の選択的低減 |
| US20140303235A1 (en) * | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| US10533172B2 (en) * | 2014-09-18 | 2020-01-14 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
| WO2017147536A1 (en) * | 2016-02-24 | 2017-08-31 | The Rockefeller University | Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof |
| US12281305B2 (en) * | 2018-11-21 | 2025-04-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
-
2022
- 2022-01-28 JP JP2023546047A patent/JP2024505226A/ja active Pending
- 2022-01-28 CN CN202280012172.3A patent/CN116940683A/zh active Pending
- 2022-01-28 AU AU2022213384A patent/AU2022213384A1/en active Pending
- 2022-01-28 MX MX2023008922A patent/MX2023008922A/es unknown
- 2022-01-28 EP EP22746658.8A patent/EP4284504A4/en active Pending
- 2022-01-28 KR KR1020237028631A patent/KR20230137958A/ko active Pending
- 2022-01-28 WO PCT/US2022/014231 patent/WO2022165122A1/en not_active Ceased
- 2022-01-28 CA CA3210076A patent/CA3210076A1/en active Pending
- 2022-01-28 US US18/263,194 patent/US20240376469A1/en active Pending
-
2023
- 2023-07-03 IL IL304218A patent/IL304218A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024079716A5 (enExample) | ||
| US7572582B2 (en) | Oligonucleotide analogues | |
| US6794499B2 (en) | Oligonucleotide analogues | |
| JP5677716B2 (ja) | オリゴヌクレオチド類似体を含むキット及び方法並びにオリゴヌクレオチド類似体の使用 | |
| CN1646141B (zh) | 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物 | |
| RU2145964C1 (ru) | Нуклеозиды с модифицированными сахарами и олигонуклеотиды | |
| JP2022527105A5 (enExample) | ||
| CN1066456C (zh) | 具有2'－醚基的寡核苷酸 | |
| JP2022526267A5 (enExample) | ||
| US5672697A (en) | Nucleoside 5'-methylene phosphonates | |
| ES2244957T3 (es) | Oligonucleotidos modificados, su preparacion, asi como su empleo. | |
| JP2021074021A5 (enExample) | ||
| US9169256B2 (en) | Artificial nucleic acids | |
| PT98931B (pt) | Processo para a ligacao de nucleosidos com uma ponte siloxano | |
| WO1997030064A1 (en) | Hexitol containing oligonucleotides and their use in antisense strategies | |
| JP2021522800A5 (enExample) | ||
| JP2017518966A (ja) | リン保護基ならびにそれらの調製方法および使用 | |
| JP2023549563A5 (enExample) | ||
| JP2802947B2 (ja) | 新規な２’―ハロメチリデン、２’―エテニリデン及び２’―エチニルシチジン、ウリジン及びグアノシン誘導体類 | |
| JP2025511183A5 (enExample) | ||
| JP3675847B2 (ja) | ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法 | |
| JP2023524065A5 (enExample) | ||
| JP4047814B2 (ja) | 新規カリックス［４］アレーン−ヌクレオシドおよびカリックス［４］アレーン−オリゴヌクレオチドハイブリッド | |
| JP4180681B2 (ja) | アンチセンスオリゴヌクレオチド | |
| NZ760372B2 (en) | Improved process for preparing imetelstat |